Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bristol-Myers Squibb |
---|---|
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00035633 |
The purpose of this clinical research study is to assess the safety effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen positive.
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis B |
Drug: Entecavir |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Study ID Numbers: | AI463-022 |
Study First Received: | May 4, 2002 |
Last Updated: | June 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00035633 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Anti-Infective Agents Liver Diseases Hepatitis, Chronic Hepatitis, Viral, Human Lamivudine Antiviral Agents Hepatitis |
Virus Diseases Digestive System Diseases Entecavir Hepatitis B, Chronic Hepatitis B DNA Virus Infections |
Anti-Infective Agents Liver Diseases Hepatitis, Chronic Hepatitis, Viral, Human Hepadnaviridae Infections Antiviral Agents Pharmacologic Actions Hepatitis |
Virus Diseases Digestive System Diseases Entecavir Therapeutic Uses Hepatitis B, Chronic Hepatitis B DNA Virus Infections |